{"id":"W2888893923","doi":"10.1016/j.atherosclerosis.2018.08.036","title":"Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: An open-label extension of the ODYSSEY program","year":2018,"lang":"en","type":"article","venue":"Atherosclerosis","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":58,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université de Montréal; Montreal Clinical Research Institute","funders":"Aegerion Pharmaceuticals; Seventh Framework Programme; Nederlandse Organisatie voor Wetenschappelijk Onderzoek; Orion Corporation; Amarin Corporation; Regeneron Pharmaceuticals; Sanofi; European Commission; Pfizer; Amgen","keywords":"Familial hypercholesterolemia; Alirocumab; Extension (predicate logic); Term (time); Medicine; Open label; Internal medicine; Adverse effect; Cholesterol; Computer science; Lipoprotein; Physics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003811556,0.0001801506,0.0005307918,0.00004799948,0.00009023046,0.00002008569,0.0002405246,0.0001232618,0.000006115843],"category_scores_gemma":[0.00003628748,0.0001086975,0.00005687958,0.0002488735,0.0003108938,0.0001397037,0.0002019395,0.0001671115,0.000001211504],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005256386,"about_ca_system_score_gemma":0.00006759995,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005955208,"about_ca_topic_score_gemma":0.0002631643,"domain_scores_codex":[0.9983706,0.0001441828,0.0003977885,0.0003790181,0.0004552056,0.0002531731],"domain_scores_gemma":[0.9985598,0.00001857402,0.0001649295,0.0009368363,0.000203799,0.0001160106],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.002121743,0.002976346,0.8066198,0.0001445691,0.00009046081,9.552336e-7,0.0006479723,9.545395e-7,0.007516126,0.000006386038,0.000004674413,0.17987],"study_design_scores_gemma":[0.01556168,0.005591462,0.9755014,0.0007054437,0.0001100072,0.000004955847,0.00002793875,0.00001481239,0.002344048,0.000002221925,0.00002685046,0.0001091759],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9974768,0.00008467131,0.00002270517,0.0000583814,0.00006711203,0.002208103,0.00001451213,0.00001997169,0.00004772127],"genre_scores_gemma":[0.9989635,0.00007686221,0.0006193741,0.000184799,0.00005567757,0.00003279991,0.000013917,0.00003842822,0.00001459079],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1797608,"threshold_uncertainty_score":0.4432554,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02839801831121224,"score_gpt":0.293402990230041,"score_spread":0.2650049719188288,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}